Compare EDIT & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDIT | ACU |
|---|---|---|
| Founded | 2013 | 1867 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 175.3M |
| IPO Year | 2016 | 1994 |
| Metric | EDIT | ACU |
|---|---|---|
| Price | $2.86 | $42.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $4.92 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.6M | 16.8K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | ★ 37.50 | 1.63 |
| EPS | N/A | ★ 2.49 |
| Revenue | $31,937,000.00 | ★ $196,541,816.00 |
| Revenue This Year | N/A | $5.67 |
| Revenue Next Year | N/A | $5.25 |
| P/E Ratio | ★ N/A | $16.67 |
| Revenue Growth | ★ 132.64 | 1.05 |
| 52 Week Low | $1.29 | $35.50 |
| 52 Week High | $4.54 | $47.31 |
| Indicator | EDIT | ACU |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 37.82 |
| Support Level | $1.95 | $39.29 |
| Resistance Level | $3.17 | $44.31 |
| Average True Range (ATR) | 0.26 | 1.48 |
| MACD | -0.05 | -0.39 |
| Stochastic Oscillator | 17.95 | 3.76 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.